Table 1 Responses and adverse events
Study/report | Timing of administration of rituximab | Response | Adverse events |
|---|---|---|---|
Shimada et al. [3] | 1st: 23 cases | NA | 10 of 23 cases developed infusion reactions; hypoxia was observed in 3 of the 10 cases and Grade 3 severe hypoxia in 1 case |
Shimada et al. [3] | 2nd: 25 cases | NA | 4 of 25 cases developed infusion reactions |
Ohkubo et al. [23] | 1st | CR | None |
Imahashi et al. [15] | 1st | CR | NA |
Aoyama et al. [14] | 1st | NC | Grade 3 sick sinus syndrome |
Kaku et al. [16] | 1st | CR | None |
Okachi et al. [24] | 1st: 2 cases | CR | NA |
Wakamatsu et al. [34] | 1st | CR | NA |
Shimizu et al. [27] | 1st: 5 cases | CR | NA |
Takahashi et al. [31] | 1st | CR | NA |
Tanikawa et al. [33] | 1st | NC | NA |
Sawa et al. [26] | 1st | CR | NA |
Watanabe et al. [35] | 1st | CR | NA |
Sakurai et al. [25] | 1st | CR | NA |
Takizawa et al. [32] | 1st | CR | NA |
Nakano et al. [22] | 1st | NC | NA |
Kotake et al. [21] | 2nd | CR | NA |
Shinoda et al. [28] | 2nd | CR | NA |
Shimada et al. [1] | 2nd | CR | None |
Ishizuka et al. [17] | 2nd | CR | NA |
Iwagami et al. [18] | 2nd | CR | NA |
Kashizaki et al. [19] | 2nd | CR | Unspecified* |
Kobayashi et al. [20] | 2nd | PR | NA |
Sakurai et al. [25] | 2nd | CR | None |
Suzuki et al. [29] | 2nd | CR | NA |
Tadokoro et al. [30] | 2nd | CR | NA |
Our other case | 1st | CR | Grade 1 fever, chills, hypoxia |
Present case | 1st | NA | Death |